EUCTR2005-005450-45-IT进行中（未招募）不适用
A double blind, randomized, placebo-controlled, parallel group, multicenter/multinational, efficacy and safety study of desloratadine 5 mg in the treatment of subjects with allergic rhinitis who meet the criteria for Persistent Allergic Rhinitis PER . - ND
SCHERING-PLOUGH0 个研究点目标入组 800 人开始时间: 2006年12月6日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 800
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects 12 years of age or older, of either sex with at least a 2 year history of allergic rhinitis who meet the criteria for PER defined as symptoms of allergic rhinitis that are present for four days or more per week and for four or more consecutive weeks per year .
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects with history of anaphylaxis and/or severe local reactions to skin testing with allergens or with intolerable symptoms that would make partecipating in the study unbearable. Subjects who have had an upper respiratory tract that required antibiotic therapy, with asthma who require chronic use of inhaled or systemic corticosteroids or with clinically significan sinusitis.
研究者
相似试验
进行中（未招募）
1 期
A double blind, randomized, placebo-controlled, parallel group, multicenter Phase 3 pivotal study to assess the safety and efficacy of 1mg/kg/day intravenous DP-b99 over 4 consecutive days versus placebo when initiated within nine hours of acute ischemic stroke onset - MACSIAcute Ischemic StrokeMedDRA version: 12.0Level: LLTClassification code 10055221Term: Ischemic strokeEUCTR2009-012025-11-FRD-Pharm Ltd.770
进行中（未招募）
不适用
Study of Sativex for the Treatment of Cancer Related Pain.Pain in patients with advanced cancer who experience inadequate analgesia during optimized chronic opioid therapy.MedDRA version: 14.1Level: PTClassification code 10058019Term: Cancer painSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-016065-29-GBGW Pharma Ltd.380
进行中（未招募）
不适用
A double blind, randomized, placebo-controlled, parallel group, multicenter Phase 3 pivotal study to assess the safety and efficacy of 1mg/kg/day intravenous DP-b99 over 4 consecutive days versus placebo when initiated within nine hours of acute ischemic stroke onset - MACSIAcute Ischemic StrokeStroke is the most common neurologic disorder and is the third leading cause of death in developed countries, after myocardial infarction and cancer. Stroke is the second leading cause of neurological morbidity in the United States, Europe, and Japan. 67%- 81% of all stroke cases are ischemic strokes.MedDRA version: 12.0Level: LLTClassification code 10055221Term: Ischemic strokeEUCTR2009-012025-11-NLD-Pharm Ltd.770
进行中（未招募）
不适用
Study of Sativex for the Treatment of Cancer Related Pain.Pain in patients with advanced cancer, who experience inadequate analgesia during optimized chronic opioid therapy.MedDRA version: 14.1Level: PTClassification code 10058019Term: Cancer painSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-016064-36-LTGW Pharma Ltd380
进行中（未招募）
1 期
Study of Sativex for the Treatment of Cancer Related Pain.Pain in patients with advanced cancer, who experience inadequate analgesia during optimized chronic opoid therapy.MedDRA version: 14.1Level: PTClassification code 10058019Term: Cancer painSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-016065-29-DEGW Pharma Ltd.380